Date of Award


Degree Type

Selective Evidence-Based Medicine Review

Degree Name

Master of Science in Health Sciences - Physician Assistant


Physician Assistant Studies

Department Chair

John Cavenagh, MBA, PhD, PA-C


OBJECTIVE: The Objective of this selective EBM review is to determine where or not, “Is Incidence of Nausea Influenced by Brintellix (Vortioxetine) in Patients over the Age of 18 with Major Depressive Disorder (MDD)?”

STUDY DESIGN: Review of three English language primary studies, published between 2011 and 2013

DATA SOUCES: Three double blind randomized controlled trials (RCTs). Sources were found on PubMed and Cochrane Library databases.

OUTCOMES MEASURED: To measure the incidence of nausea in patients over 18 who are diagnosed with major depressive disorder taking Brintellix compared to a placebo.

RESULTS: The randomized controlled studies results found that Brintellix was found to increase incidence of nausea when compared to placebo.

CONCLUSION: Brintellix treatment was well tolerated in patients 18 years and older with major depressive disorder; with nausea being the most common adverse event reported from patients.